表紙
市場調査レポート

世界の前立腺がん治療薬市場の将来動向

Global Prostate Cancer Drugs Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 318308
出版日 ページ情報 英文 71 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
世界の前立腺がん治療薬市場の将来動向 Global Prostate Cancer Drugs Market 2014-2018
出版日: 2014年11月05日 ページ情報: 英文 71 Pages
概要

前立腺がんとは、前立腺(精液の分泌を司る、男性の生殖系の外分泌腺)で発症する癌の一種です。前立腺がんは、65歳以上の男性が主に発症することが多く、逆に40歳以下の男性が発症する事例はごく少ないです。世界の前立腺がん治療薬市場の2013〜2018年の年平均成長率(CAGR)は10.45%に達する、と予測されています。

当レポートでは、全世界の前立腺がん治療薬の市場について分析し、疾患・治療法の概要や基本的な市場構造、薬剤開発・治験の進行状況、市場規模の動向(今後5年間の予測値)、地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブ・サマリー

第2章 略語集

第3章 分析範囲

  • 市場概要
  • 主な製品

第4章 市場分析の手法

  • 市場分析のプロセス
  • 分析手法

第5章 イントロダクション

第6章 市場環境

  • 市場概況
  • 市場規模とその予測
  • ファイブフォース分析

第7章 パイプライン製品の現状

第8章 発症率・有病率

  • 米国
  • 欧州

第9章 前立腺がんの治療経路

第10章 前立腺がんの治療オプション

第11章 進行性前立腺がんの解説

第12章 前立腺がん治療の現在の状況

第13章 NCI(全米がん研究所)の前立腺がん研究の進行状況

第14章 カテゴリー別の市場分析

第15章 地域別の分析

第16章 購入基準

第17章 市場の成長促進要因

第18章 促進要因とその影響力

第19章 市場の課題

第20章 促進要因・課題の影響力

第21章 市場の傾向

第22章 市場動向とその影響

第23章 ベンダー環境

  • 競争シナリオ
    • 近年の主な動向
    • 企業合併・買収(M&A)

第24章 主要ベンダーの分析

  • AbbVie Inc.
    • 主要データ
    • 事業概要
    • 部門別の市場収益額(最新値)
    • 部門別の市場収益額(前年度との比較)
    • 地域別の売上高
    • 事業戦略
    • 最近の発展動向
    • SWOT分析
  • AstraZeneca plc
  • Janssen Pharmaceuticals
  • Sanofi

第25章 関連レポート

図表一覧

目次
Product Code: IRTNTR4587

About Prostate Cancer

Prostate cancer initiates in the prostate, which is an exocrine gland present in the male reproductive system. The main function of the prostate is to make fluid for semen. The risk of developing prostate cancer is age dependent. Prostate cancer affects mostly men over the age of 65 and rarely occurs in men younger than 40 years of age.

TechNavio's analysts forecast the Global Prostate Cancer Drugs market to grow at a CAGR of 10.45 percent over the period 2013-2018.

Covered in this Report

The Global Prostate Cancer Drugs market can be divided into four segments: Hormonal Therapy, Chemo Therapy, Immuno Therapy and Targeted Therapy. This report covers the present scenario and the growth prospects of the Global Prostate Cancer Drugs market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the form of hormonal therapy, chemo therapy, immuno therapy, and targeted therapy for prostate cancer that are available in the market.

TechNavio's report, the Global Prostate Cancer Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Prostate Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Abbvie
  • Astra Zeneca
  • Janssen Pharmaceuticals
  • Sanofi

Other Prominent Vendors

  • Amgen
  • Astellas Pharma
  • Bayer
  • BMS
  • Dendreon
  • Endo Pharmaceuticals
  • Ferring Pharmaceutical
  • F. Hoffmann-La Roche
  • GSK
  • Ipsen
  • Medivation
  • Merck
  • Novartis
  • Pfizer
  • Teva Pharmaceuticals

Market Driver

  • Increase in Global Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Prostate Cancer Drugs
  • For a full, detailed list, view our report

Market Trend

  • Major Opportunities for Pharmaceutical Companies
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

    • 08.1.1. US
    • 08.1.2. Europe

09. Prostate Cancer Treatment Path

10. Prostate Cancer Treatment Options

11. Interpretation of Advanced Prostate Cancer

12. Current Landscape of Prostate Cancer Treatments

13. NCI Prostate Cancer Research Portfolio

14. Market Segmentation by Category

15. Geographical Segmentation

16. Buying Criteria

17. Market Growth Drivers

18. Drivers and their Impact

19. Market Challenges

20. Impact of Drivers and Challenges

21. Market Trends

22. Trends and their Impact

23. Vendor Landscape

  • 23.1. Competitive Scenario
    • 23.1.1. Key News
    • 23.1.2. Mergers and Acquisitions
  • 23.2. Market Share Analysis 2013
  • 23.3. Other Prominent Vendors

24. Key Vendor Analysis

  • 24.1. AbbVie Inc.
    • 24.1.1. Key Facts
    • 24.1.2. Business Overview
    • 24.1.3. Product Segmentation by Revenue 2013
    • 24.1.4. Product Segmentation by Revenue 2012 and 2013
    • 24.1.5. Sales by Geography
    • 24.1.6. Business Strategy
    • 24.1.7. Key Developments
    • 24.1.8. SWOT Analysis
  • 24.2. AstraZeneca plc
    • 24.2.1. Key Facts
    • 24.2.2. Business Description
    • 24.2.3. Business Segmentation
    • 24.2.4. Business Strategy
    • 24.2.5. Revenue by Business Segmentation
    • 24.2.6. Revenue Comparison 2011-2013
    • 24.2.7. Sales Revenue by Geographical Segmentation
    • 24.2.8. Key Developments
    • 24.2.9. SWOT Analysis
  • 24.3. Janssen Pharmaceuticals
    • 24.3.1. Key Facts
    • 24.3.2. Business Overview
    • 24.3.3. Recent Developments
    • 24.3.4. SWOT Analysis
  • 24.4. Sanofi
    • 24.4.1. Key Facts
    • 24.4.2. Business Description
    • 24.4.3. Business Segmentation
    • 24.4.4. Revenue by Business Segmentation
    • 24.4.5. Revenue Comparison 2012 and 2013
    • 24.4.6. Sales by Geography
    • 24.4.7. Business Strategy
    • 24.4.8. Key Developments
    • 24.4.9. SWOT Analysis

25. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Prostate Cancer Drugs Market 2013-2018 (US$ billion)
  • Exhibit 3: Clinical Trial Map of JNJ56021927/ARN-509
  • Exhibit 4: Clinical Trial Map of Zytiga
  • Exhibit 5: Clinical Trial Map of Docetaxel
  • Exhibit 6: Clinical Trial Map of Lapatinib Ditosylate
  • Exhibit 7: Clinical Trial Map of AZD5312
  • Exhibit 8: Rate of New Prostate Cancer Cases by Race and Ethnicity: US
  • Exhibit 9: Proportion of US Males with Prostate Cancer
  • Exhibit 10: Percentage of Total Dollars Contribution by Scientific Area in Fiscal Year 2012
  • Exhibit 11: Global Prostate Cancer Drugs Market Segmentation by Category
  • Exhibit 12: Global Prostate Cancer Drugs Market by Geographical Segmentation 2013
  • Exhibit 13: AstraZeneca Sales by Therapy Area 2013
  • Exhibit 14: J&J Market Sales by therapeutic Area (Pharmaceuticals) 2013
  • Exhibit 15: J&J Market Sales by Major Franchise (Medical Devices and Diagnostics) 2013
  • Exhibit 16: AbbVie Inc.: Product Segmentation by Revenue 2013
  • Exhibit 17: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 18: AbbVie Inc.: Sales by Geography 2013
  • Exhibit 19: AstraZeneca: Business Segmentation
  • Exhibit 20: AstraZeneca: Revenue by Business Segmentation 2013
  • Exhibit 21: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 22: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 23: Sanofi SA: Business Segmentation
  • Exhibit 24: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 25: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 26: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top